Startseite Medizin Prevalence of medically treated children with ADHD and type 1 diabetes in Germany – Analysis of two representative databases
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Prevalence of medically treated children with ADHD and type 1 diabetes in Germany – Analysis of two representative databases

  • Thomas M. Kapellen EMAIL logo , Rebecca Reimann , Wieland Kiess und Karel Kostev EMAIL logo
Veröffentlicht/Copyright: 18. Oktober 2016

Abstract

Background:

The aim of this study was to analyze the prevalence of attention deficit hyperactivity disorder (ADHD) in children and adolescents with type 1 diabetes mellitus (T1DM) in Germany.

Methods:

Two different representative German databases – IMS®-Disease Analyzer, a database that includes diagnoses as well as other information, and IMS®-LRx, a database that documents prescriptions – were used to conduct a retrospective analysis. We searched the LRx database for patients who received both insulin and ADHD-specific medication.

Results:

In 2014, 677,587 children and adolescents aged 0–18 years were treated by a pediatrician and documented in the Disease Analyzer database. Of these patients, 16,833 received the International Statistical Classification of Diseases and Related Health Problems (ICD-10) diagnosis of ADHD (2.5%) and 3668 patients were treated for T1DM (0.1%). Of these 3668 patients, a total of 153 children were also diagnosed with ADHD (4.2%; p<0.05). In the LRx database, the overall prevalence of children in Germany who received both drugs for the treatment of ADHD and insulin in 2014 amounted to 2.9%. Diagnosis of ADHD is 2.4–3.3 times more frequent in boys than in girls. The highest prevalence was seen in the age group of 12–15 years (3.5%) and the lowest in the age group of 6–11 years (2.5%).

Conclusions:

Children with diabetes suffer from ADHD significantly more frequently than children without diabetes. The prevalence of medically treated children with ADHD and diabetes is similar to that documented in a recent report by the Barmer GEK health insurance body. However, it is possible that children with T1DM are much more frequently seen by medical care providers and are thus more likely to be evaluated and receive an appropriate diagnosis.


Corresponding authors: PD Dr. Thomas M. Kapellen, MD, Universität Leipzig, Klinik für Kinder und Jugendliche, Liebigstr. 20 A, D-04103 Leipzig, Germany, Phone: 0049-341-9712320, Fax: 0049-341-9712329; and Prof. Dr. Karel Kostev, IMS Health, Epidemiology, Darmstädter Landstr. 108, 60598 Frankfurt am Main, Frankfurt, Germany, Phone: 0049-69-66044878, Fax: 0049-69-66045878

Acknowledgment

T.K. planned the study and wrote the article, R.R. conducted the study in cooperation with K.K. and edited the article. K.K. did the statistical work. W.K. reviewed and edited the article.

  1. Conflict of interest statement: The authors declare that there is no conflict of interest.

References

1. AG ADHS Arbeitsgemeinschaft ADHS der Kinder- und Jugendärzte e. V. (ed.): Leitlinie ADHS bei Kindern und Jugendlichen 2007. Online verfügbar unter: www.ag-adhs.de.Suche in Google Scholar

2. Schlander M, Trott G-E, Schwarz O. Gesundheitsökonomie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung in Deutschland. Nervenarzt 2010;81:289–300.10.1007/s00115-009-2888-9Suche in Google Scholar PubMed

3. Banaschewski T, Poustka L, Holtmann M. Autismus und ADHS über die Lebensspanne. Nervenarzt 2011;82:573–81.10.1007/s00115-010-3239-6Suche in Google Scholar PubMed

4. Huss M, Hölling H, Kurth B, Schlack R. How often are German children and adolescents diagnosed with ADHD? Prevalence based on the judgment of health care professionals: results of the German health and examination survey (KiGGS). Eur Child Adolesc Psychiatry 2008;17(Suppl 1):52–8.10.1007/s00787-008-1006-zSuche in Google Scholar PubMed

5. Knopf H, Hölling H, Huss M, Schlack R. Prevalence, determinants and spectrum of attention-deficit hyperactivity disorder (ADHD) medication of children and adolescents in Germany: results of the German Health Interview and Examination Survey (KiGGS). BMJ Open 2012;2:e000477.10.1136/bmjopen-2011-000477Suche in Google Scholar PubMed PubMed Central

6. Barmer GE, editor. Barmer GEK Arztreport 2013. Schwerpunkt: ADHS. Asgard, Siegburg.Suche in Google Scholar

7. Kiess W, Gorski T, Penke M, Klamt S, Kapellen TM. Diabetes mellitus in children and adolescents – a global epidemic which has become neglected. J Pediatr Endocrinol Metab 2015;28:247–50.10.1515/jpem-2015-0900Suche in Google Scholar PubMed

8. Butwicka A, Frisén L, Almqvist C, Zethelius B, Lichtenstein P. Risks of psychiatric disorders and suicide attempts in children and adolescents with type 1 diabetes: a population-based cohort study. Diabetes Care 2015;38:453–9.10.2337/dc14-0262Suche in Google Scholar PubMed PubMed Central

9. Galler A, Bollow E, Meusers M, Bartus B, Näke A, et al. Comparison of glycemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian Diabetes Survey (DPV). Diabetes Care 2015;38:1051–7.10.2337/dc14-2538Suche in Google Scholar PubMed

10. Chen HJ, Lee YJ, Yeh GC, Lin HC. Association of attention-deficit/hyperactivity disorder with diabetes: a population-based study. Pediatr Res 2013;73:492–6.10.1038/pr.2013.5Suche in Google Scholar PubMed

11. Hilgard D, Konrad K, Meusers M, Bartus B, Otto KP, et al. Comorbidity of attention deficit hyperactivity disorder and type 1 diabetes in children and adolescents: analysis based on the multicentre DPV registry. Pediatr Diabetes 2016. doi: 10.1111/pedi.12431. [Epub ahead of print].10.1111/pedi.12431Suche in Google Scholar PubMed

12. Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmaco-epidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 2009;47:617–26.10.5414/CPP47617Suche in Google Scholar PubMed

13. Richter H, Dombrowski S, Hamer H, Hadji P, Kostev K. Use of a German longitudinal prescription database (LRx) in pharmacoepidemiology. Ger Med Sci 2015;13:Doc14. doi: 10.3205/000218.10.3205/000218Suche in Google Scholar PubMed PubMed Central

14. Agrawal J, Kumar R, Malhi P, Dayal D. Prevalence of psychosocial morbidity in children with type 1 diabetes mellitus: a survey from Northern India. J Pediatr Endocrinol Metab 2016;29:893–9.10.1515/jpem-2015-0335Suche in Google Scholar PubMed

15. Mutlu EK, Mutlu C, Taskiran H, Ozgen IT. Association of physical activity level with depression, anxiety, and quality of life in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2015;28:1273–8.10.1515/jpem-2015-0082Suche in Google Scholar PubMed

16. Döpfner M, Breuer D, Wille N, Erhart M, Ravens-Sieberer U. How often do children meet ICD 10/DSM-IV criteria of attention deficit/hyperactivity disorder? Parent-based prevalence rates in a national sample – results of the BELLA study. Eur Child Adolesc Psychiatry 2008;17:59–70.10.1007/s00787-008-1007-ySuche in Google Scholar PubMed

17. Kapellen TM, Wolf J, Rosenbauer J, Stachow R, Ziegler R, et al. Changes in the use of analogue insulins in 37206 children and adolescents with type 1 diabetes in 254 centres in Germany and Austria in the last twelve years. Exp Clin Endocrinol Diabetes 2009;117:329–35.10.1055/s-0028-1103289Suche in Google Scholar PubMed

18. Scheuing N, Bächle C, Becker M, Berger G, Haberland H, et al. Mental disorder and type 1 diabetes: initiation and discontinuation of CSII in pediatric and young adult patients with ADHD, depression, eating disorder, needle phobia, anxiety or obsessive compulsive disorder or psychosis. A German/Austrian DPV analysis. Pediatr Diabetes 2014;15(Suppl 19):44.Suche in Google Scholar

19. Kapellen TM, Klinkert C, Heidtmann B, Jakisch B, Haberland H, et al. Insulin pump treatment in children and adolescents with type 1 diabetes. Experiences of the German Working group for Pediatric pump treatment. Postgrad Med 2010;122:98–105.10.3810/pgm.2010.05.2147Suche in Google Scholar PubMed

Received: 2016-5-4
Accepted: 2016-9-15
Published Online: 2016-10-18
Published in Print: 2016-11-1

©2016 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Puberty – genes, environment and clinical issues
  4. Puberty
  5. Increased levels of bisphenol A (BPA) in Thai girls with precocious puberty
  6. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty
  7. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation
  8. Original Articles
  9. Association between the triglyceride to high-density lipoprotein cholesterol ratio and insulin resistance in Korean adolescents: a nationwide population-based study
  10. Progression from impaired glucose tolerance to type 2 diabetes in obese children and adolescents: a 3–6-year cohort study in southern Thailand
  11. Investigation of the inflammatory biomarkers of metabolic syndrome in adolescents
  12. A 10-year experience using combined lipid-lowering pharmacotherapy in children and adolescents
  13. Prevalence of medically treated children with ADHD and type 1 diabetes in Germany – Analysis of two representative databases
  14. Association of short stature with life satisfaction and self-rated health in children and adolescents: the CASPIAN-IV study
  15. Case Reports
  16. Central precocious puberty in a boy with 22q13 deletion syndrome and NOTCH-1 gene duplication
  17. Non-androgen secreting adrenocortical carcinoma in preadolescence: a case report and literature review
  18. Efficacy of growth hormone therapy in Kearns-Sayre syndrome: the KIGS experience
  19. A unique case of Shwachman-Diamond syndrome presenting with congenital hypopituitarism
Heruntergeladen am 18.1.2026 von https://www.degruyterbrill.com/document/doi/10.1515/jpem-2016-0171/pdf
Button zum nach oben scrollen